Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2013

View Archived Issues

Results show excellent reproducibility of in vivo [11C]-PBR-28 binding in MS

Recombinant BCG vaccine found safe and immunogenic in phase I study

Ferumoxytol-enhanced MRI shows potential for neuroimaging of patients with HAND

Identification of a novel DYRK1A inhibitor with the potential to prevent memory impairment in vivo

In vivo results suggest HIS-601 is a promising candidate for metabolic disorders

Merrimack Pharmaceuticals reports phase II MM-121 study results

Aragon Pharmaceuticals doses first patient in phase I study of ARN-810

X-Body Biosciences forms therapeutic antibody alliance

Gene silencing construct Tribetarna increases survival in lung cancer model

Promising interim results seen in phase III Lymphoseek trial in head and neck cancer

Astellas to collaborate with Ambrx on antibody-drug conjugates for cancer

Arena Pharmaceuticals begins phase I trial of APD-334

New antimalarial agents prepared at CSIR

Covis Pharma to acquire U.S. rights to several sanofi-aventis drugs

Otsuka Pharmaceutical patents novel prodrugs of brexpiprazole

Vertex and Bristol-Myers Squibb to conduct phase II studies of VX-135 and daclatasvir

Vital Therapies enrolls first patient in phase III trial of the ELAD system

A*STAR and Singapore Health Services synthesize new agents for bacterial infections

Clinical data on OTX-008 presented at AACR meeting

Blanchette Rockefeller Neurosciences Institute and Neurotrope BioScience form collaboration

VaxInnate receives NIH grant to develop recombinant tetravalent dengue vaccine

Novel itraconazole analogues designed by Johns Hopkins University

Roche presents new compounds for atherosclerosis and other disorders

Shire commences two phase II studies of product designed to facilitate hemodialysis

EMA extends review of Scenesse MAA for erythropoietic protoporphyria

FDA grants priority review for Bayer's riociguat NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...